Cancer treatment
Novel Dual-Payload ADC Platform Demonstrates Enhanced Antitumor Efficacy and Overcomes Drug Resistance
Researchers in Chengdu, People's Republic of China, have discovered a new strategy for overcoming tumor resistance, offering a promising therapeutic outcome for cancer patients. The innovative dual-payload antibody-drug conjugate (ADC) platform integrates exatecan and triptolide to enhance antitumor efficacy and overcome resistance. This groundbreaking research has been peer-reviewed